Five Reasons Illumina Should Stay Independent

March 5, 2012

March 6, 2012 | The Illumina-Roche acquisition dance continues and Luke Timmerman at Xconomy says that if the low-ball takeover happens, it would be, "bad for Illumina shareholders, bad for the genetic tools industry, bad for science, bad for the San Diego innovation community, and bad for the personalized medicine movement." He calls for a rejection of Roche's offer. Xconomy